The primary aim of this analysis was to examine the quantitative features of antibody–
antigen interactions in tumors and normal tissue after parenteral administration of antitumor …

Radioimmunotherapy (RIT) could be a possible adjuvant treatment method for patients with
colorectal carcinoma. The A33 antigen is a promising RIT target, as it is highly and …

Humanized A33 (huA33) is a promising monoclonal antibody that recognizes A33 antigen,
which is present in more than 95% of colorectal cancers and in normal bowel. In this study …

Radiolabeling monoclonal antibodies (mAbs) allows the evaluation of biodistribution of
constructs in vivo through gamma camera imaging and also permits quantitation of mAb …

INTRODUCTION: The humanized monoclonal antibody A33 (huA33) is a potential targeting
agent against colorectal carcinoma since the A33 antigen is highly and homogenously …

The humanized antibody A33 binds to the A33 antigen, expressed in 95% of primary and
metastatic colorectal carcinomas. The restricted pattern of expression in normal tissue …

Purpose: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is
expressed on 95% of colorectal cancers. A previous study has shown excellent tumor …

Objective: The 4.2-day half-life of 124I favors its use for positron emission tomography (PET)
of monoclonal antibodies (mAbs). However, high positron energy and β+-associated …

Immuno-PET is an appealing concept in the detection of tumors and planning of antibody-
based therapy. For this purpose, the long-lived positron emitter 89Zr (half-life, 78.4 h) …

huA33 is a humanized antibody that targets the A33 antigen, which is highly expressed in
intestinal epithelium and more than 95% of human colon cancers but not other normal …